Medical experts will benefit from information about new mechanistic disease hypotheses, disease risk models, longitudinal disease progression and clinical studies with available data for validation and analyses. In particular,in AETIONOMY we want to overcome historical disease taxonomies for Alzheimer's and Parkinson's disease and target new methods using public available information from medical publications and medical data. The outcome resulted in new hypotheses for both diseases which are described by new mechanistic processes, involved pathways and biomarkers giving indications of the disease stage and progression. Naturally, this group is most interested in associations between these hypotheses and patient data as the ultimate goal will be the translation of these findings into clinical practice (following the IMI perspective ‘diagnostic and treatment biomarkers for diseases clearly linked to clinical relevance and approved by regulators’).
Therefore, below we address this group through the following topics: